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ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a fast progressing neurodegenerative disease leading to 
quadriplegia, anarthria and respiratory insufficiency. A large variety of phenotypes and disability progression 
requires individually tailored management. Identification of predictors of poor prognosis may not only improve 
management, but also allow for more precise patients’ stratification for clinical trials or research studies. The 
aim of the study was to investigate the influence of emotional lability present at disease onset on ALS 
progression by exploring its direct impact on the decay of the ALS Functional Rating Scale-Revised (ALSFRS-
R). The study was performed in a group of 1145 patients from Germany, Poland, Portugal and Turkey between 
2014 and 2018. The analysis showed that the presence of emotional lability at ALS onset was linked to a faster 
decline of ALSFRS-R (0.70 vs 0.50, p<0.0001), in case of either bulbar (0.80 vs 0.65, p<0.05) or limb disease 
onset (0.59 vs 0.46, p <0.01). It was most prominent in the bulbar subscore of ALSFRS-R. A multiple regression 
analysis showed a direct influence of emotional lability at ALS onset on disease progression, regardless of age, 
gender, site of onset, weight loss, cognitive impairment and diagnosis delay (β=0.071; p=0.019). It can therefore 
be concluded that the presence of emotional lability at the disease onset is an independent factor of faster 
disease progression in ALS. 
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Amyotrophic lateral sclerosis (ALS) is a fast progressing 
neurodegenerative disease leading to quadriplegia, 
anarthria and respiratory insufficiency. A large variety of 
phenotypes and progression of disability requires 
individually tailored management. Numerous studies are 
conducted every year with the scope to understand the 
disease pathogenesis and identify the most promising 
pathways and molecular targets [1-3]. Clinical 
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significance of these studies is determined by accurate 
patients’ characterisation, taking into account not only 
the demographic and clinical factors, but also predictors 
of a poorer prognosis, in order to exclude their direct 
influence on the study outcome [4-6]. 
Beside motor neurons, ALS may involve the 
frontotemporal cortex, as well as extrapyramidal and 
autonomous systems [7, 8]. The extra-motor 
involvement in ALS is mainly subclinical [9]. The main 
non-motors symptoms of ALS include cognitive 
impairment (language and executive dysfunction) and 
emotional lability (EL), also known as pseudobulbar 
affect, pathological laughing and crying or emotional 
incontinence [10]. EL may be either present at ALS 
onset or develop with the disease progression. It occurs 
in up to 50% of patients throughout the disease course 
and is more frequently present in females [11]. The 
mechanism of EL remains unclear, as it probably 
involves damage of motor and temporal cortex and the 
disinhibition of brainstem and a putative centre for 
laughing and crying [11-15]. EL is characterised by 
involuntary outbursts of crying and/or laughing (less 
commonly). The episodes usually appear spontaneously 
or are triggered by minor emotional stimuli and cannot 
be controlled [10]. Since patients preserve insight into 
their condition, the emotional outbursts cause major 
distress, affecting the quality of the everyday-life. The 
treatment of EL comprises antidepressive drugs, 
including tricyclic antidepressants (amitriptyline, 
nortriptyline) and selective serotonin reuptake inhibitors 
(fluoxetine, sertraline, citalopram, paroxetine). A 
combination of dextromethorphan and quinidine, 
affecting glutamate and serotonin pathways, has been 
shown effective in reducing the laughing/crying episodes 
as well as improving the quality of life and relationships 
in ALS patients [16, 17]. The treatment is only partially 
effective. 
In the majority of cases, EL occurs independently of 
depression, however the two conditions may coexist in 
some patients [18]. As different treatment approaches 
may be required, it is important to distinguish the EL 
from mood alterations. The clinical evaluation can be 
aided by diagnostic tools. It has been shown that the 
Center for Neurologic Study-Lability Scale (CNS-LS) 
and Hamilton Rating Scale for Depression (HRSD) do 
not correlate in ALS patients, which suggests a different 
pathomechanism of EL and affective disorders [18]. As 
up to 50% of ALS patients may experience cognitive 
impairment, the early detection of behavioral disturbance 
may help introduce the optimal care. Importantly, at 
early stages the dementia with a predominant 
involvement of the prefrontal cortex may mimic the 
episodes of EL, as frequent mood changes may be 
present in both conditions. The differential diagnosis 
may require a detailed assessment of a patient’s 
functional and cognitive capabilities. It needs to be 
emphasized that EL is considered a separate disorder, as 
no correlation has been found in any aspect of cognitive 
profile and EL in ALS patients [19]. 
The aim of our study was to assess the impact of EL 
at ALS onset on disease progression. To our knowledge, 
this is the first study concerning the impact of EL on the 
disease progression rate.  
 




The analysis included 1145 consecutive patients from 
Germany, Poland, Portugal and Turkey with definite, 
probable or possible ALS according to the revised El 
Escorial criteria [20]. The data were collected cross-
sectionally over a period of 4 years within the JPND 
project ONTology-based Web Database for 
Understanding Amyotrophic Lateral Sclerosis - 
ONWebDUALS. The disease onset was defined as the 
occurrence of the first muscles weakness. The disease 
duration was measured from the time of the first 
symptoms onset till the date of the clinical evaluation. 
EL at disease onset (ELO) was assessed based on a 
direct question whether the patient had experienced 
outbursts of uncontrollable laughing and/or crying from 
the beginning of the disease, accompanied by a detailed 
description of EL as the occurrence of laughing and/or 
crying episodes due to adequate although mild stimuli 
(p.ex. talking about the family/disease, watching 
movies/sports) or even without thinking of anything 
happy or sad, with a feeling of lability in controlling the 
presentation of emotions, without a concurrent alteration 
in the experience of emotions (mood alterations). In the 
vast majority cases the obtained information was 
confirmed by or obtained in the presence of the 
caregiver/s. The weight loss was defined as a reduction 
of the body weight of at least 10% in 36 months before 
the onset of the symptoms. The depression and cognitive 
impairment were assessed as binary variables (presence 
or absence of depression or cognitive impairment, 
respectively). It followed an individual discussion with 
the patient. For “depression” it concerned constant mood 
disturbances, feeling of worthlessness or excessive guilt, 
loss/increase of appetite, night rest/sleep alterations, loss 
of energy or interest, with each symptom experienced for 
a period of at least 2 weeks. For the “cognitive 
impairment” it included the presence of memory deficits, 
language impairment, personality or behavioural 
changes, impaired ability to perform daily tasks.  
In order to confirm the significance of the above 
evaluations, in a subgroup of patients the results were 
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compared to the Edinburgh Cognitive and Behavioural 
ALS Screen (ECAS, n=191) and the ALS Depression 
Inventory (ADI-12, n=62). We also examined the 
differences between patients with and without EL with 
regard to ECAS and ADI-12 scales. 
 
Table 1. Patients’ baseline characteristics. 
 










    Female 

















Age at time of evaluation (years ± SD) 61.6±12.79 61.7±12.32 61.6±12.89 =0.93* 
Disease characteristics 
Site of onset (%) 
    Bulbar 

















Emotional lability at onset (%) 
    Yes 













Cognitive impairment at onset (%) 
    Yes 













Initial weight loss (%) 
    Yes 














*Chi-square test (for categorical variables) and t-Student (for continues variables). ELO(+) = patients with emotional lability at disease 




The disease progression was evaluated with ALSFRS-R 
(ALS Functional Rating Scale Revised) decline rate, 
calculated as a quotient of a difference between 
ALSFRS-R score at symptoms onset (presumed as 
normal score of 48 points) and ALSFRS-R score at time 
of patient ś evaluation by a difference between the date 
of evaluation and the date of symptoms onset expressed 
in months [48 – ALSFRS-R/the date of clinical 
evaluation – the date of disease onset]. The diagnosis 
delay was defined as the time from the first symptoms 
onset to the ALS diagnosis. 
Statistical analysis 
 
Chi-square and t-Student tests were used for the 
comparisons between groups. Binary predictors of faster 
progression were investigated with Mann–Whitney U-
test and continuous predictors with simple regression 
analysis. A two-way ANOVA was conducted to detect a 
interaction between depression and EL concerning 
disease progression. Multiple regression analysis was 
applied to explore the direct influence of all confounding 
factors. A p-value of 0.05 was considered for statistical 
significance. Analyses were performed in SPSS v25.0 
software (IBM SPSS Statistics). 
 
Table 2. ALSFRS-R decline rate in terms of bulbar, motor, and respiratory function subscore. 
 














 ELO(+) ELO(-)  ELO(+) ELO(-)  ELO(+) ELO(-)  
All patients 0.21 0.06 <0.0001 0.39 0.34 =0.14 0.03 0.00 <0.005 
Bulbar onset 
patients 
0.39 0.31 <0.05 0.33 0.23 =0.16 0.08 0.00 <0.05 
Limb onset 
patients 
0.07 0.01 <0.0001 0.43 0.36 =0.06 0.00 0.00 =0.41 
 
*Mann-Whitney test. ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised; ELO(+) = patients with emotional lability at 
disease onset; ELO(-) = patients without emotional lability at disease onset. 
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The mean age at the time of evaluation was 61.6 (SD ± 
12.79) years, with male to female ratio of 1.26. Bulbar 
onset was reported in 27.25% of patients and cognitive 
impairment at disease onset in 11.70% cases (Table 1). 
The median diagnosis delay was 11.01 months (Q1-Q3, 
5.98 – 20.96). 
ELO was present in 17.38% patients [ELO(+) 
group]. There were significantly more females, 
individuals with bulbar onset, initial weight loss and 
cognitive impairment as compared to ALS patients 
without ELO [ELO(-) group]. The groups did not differ 
with regard to age (Table 1). 
 
 
Table 3. The comparison of ALSFRS-R decline rates between patients with and without 
emotional lability at disease onset in terms of disease onset, weight loss and gender. 
 
 ALSFRS-R decline rate (median) p-value* 
 ELO(+) (n=199) ELO(-) (n=946)  









Weight loss at onset 
















*Mann-Whitney test. ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised; ELO(+) = 
patients with emotional lability at disease onset; ELO(-) = patients without emotional lability at disease onset. 
 
 
Subgroup evaluation of the presence of cognitive 
impairment and depression 
 
There was no significant difference between the 
subgroup assessed with ECAS (n=191) and our cohort 
(n=1145) with regard to age (p=0.59), gender (p=0.87), 
type of onset (p=0.87), occurrence of initial weight loss 
(p=0.08), diagnostic delay (p=0.85) and the decay of 
ALSFRS-R (p=0.18). The subgroup evaluated with ADI-
12 scale (n=62) did not differ relevantly from our cohort 
(n=1145) in terms of gender (p=0.66), type of onset 
(p=0.43), occurrence of initial weight loss (p=0.53), 
diagnostic delay (p=0.49) and the decay of ALSFRS-R 
(p=0.48), but it was characterised by younger age 
(p=0.04).  
The mean score of ECAS was significantly lower in 
the subgroup of patients evaluated as “cognitively 
impaired” based on the questionnaire, as compared to 
“cognitively normal” both at the time of evaluation (68.4 
[SD±19.31] vs 95.8 [SD±23.56], p<0.0001) and at the 
disease onset (82.3 [SD±31.18] vs 93.8 [SD±22.34], 
p=0.03). Significantly higher mean ADI-12 score was 
found in the group qualified with “the presence of 
depression” based on the questionnaire as compared to 
the group assessed with “the absence of depression” 
(27.3 [SD±5.52] vs 20.3 [SD±5.44], p<0.0001). As this 
subgroup differed in terms of age from our cohort, we 
adjusted this data for age, with no observed influence on 
the obtained result.  
 
Cognitive impairment, depression and emotional 
lability 
 
No significant differences of the ECAS mean score were 
found between the EL(+) and EL(-) group either at the 
disease onset (92.7 [SD±22.79] vs 92.3 [SD±24.13], 
p=0.96) nor at the time of evaluation (91.3 [SD±26.86] 
vs 92.7 [SD±23.30], p=0.76). In addition, no relevant 
difference was found between the mean ADI-12 score 
obtained in the EL(+) and EL(-) group at the time of 
evaluation (25.0 [SD±8.74] vs 25.7 [SD±4.78], p=0.67).  
 
Emotional lability as the predictor of ALS prognosis 
 
The ELO(+) was linked to a higher ALSFRS-R decline 
rate in the course of the disease as compared to ELO(-) 
patients (0.70 vs 0.50, p<0.0001). The decay of 
ALSFRS-R was faster in all three subscores: bulbar, 
motor (without reaching statistical significance) and 
respiratory. In particular, bulbar onset ALS patients had 
faster decline of bulbar (0.39 vs 0.31, p<0.05) and 
respiratory subscores of ALSFRS-R (0.08 vs 0.00, 
p<0.05), while limb onset patients presented faster decay 
of bulbar (0.07 vs 0.01, p<0.0001) subscore of ALSFRS-
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R (Table 2). A subsequent analysis of each variant group 
of binary predictors, including disease onset, initial 
weight loss and gender, revealed a significantly higher 











  Bulbar 











  Female 










Initial weight loss1 
  Yes 























*Mann-Whitney test. 1>10% in 36 months before disease onset. ALSFRS-R = Amyotrophic Lateral Sclerosis Functional 
Rating Scale - Revised. 
 
 
Other predictors of faster progression 
 
We found that bulbar onset (0.70 vs 0.48, p<0.0001), 
female gender (0.62 vs 0.49, p<0.0001) and initial 
weight loss (0.71 vs 0.47, p<0.0001) were binary 
predictors of faster progression in ALS (Table 4). 
Cognitive impairment at disease onset resulted in a 
slightly higher decay of ALSFRS-R but did not reach 
statistical significance. Age (p<0.001) and diagnosis 
delay (p<0.001) were both found to be continuous 
factors of faster disease progression. 
 







Emotional lability at onset 0.199 0.071 2.342 0.019 
Gender 0.086 0.041 1.421 0.156 
Site of onset 0.115 0.050 1.650 0.099 
Initial weight loss 0.041 0.075 2.580 0.010 
Diagnostic delay 0.010 0.260 9.008 <0.001 
Age 0.009 0.108 3.686  <0.001 
Cognitive impairment at onset 0.041 0.037  1.243 0.214 
 
 
Depression and emotional lability 
  
We investigated a relationship between the presence of 
EL and depression at the time of patients’ evaluation in 
regard to disease progression. A two-way ANOVA 
showed an independent impact of EL (p=0.007) and 
depression (p=0.006) on ALSFRS-R decline rate, with 
no interaction between the two factors (p=0.541).  
 
Multiple regression analysis 
 
Since predictors of faster ALSFRS-R decline rate were 
found more commonly in ELO(+) group, we investigated 
a direct influence of all confounding factors on the 
disease progression.  A multiple regression analysis, 
adjusted for age, gender, site of onset, diagnosis delay, 
initial weight loss, ELO and cognitive impairment at 
disease onset, was performed showing a significant 
association of ELO(+) with further decay of ALFFRS-R 




Due to its clinical characteristics, EL causes important 
distress to ALS patients and their proxy. For this reason, 
the majority of publications focus on the psychological, 
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social and therapeutic aspects of the syndrome [10, 11, 
15, 19, 21, 22]. Although the EL does not correlate with 
depression [18, 23-25], an ascending social isolation may 
indeed result in development of mood alterations, 
depression and further functional impairment [26, 27]. 
The EL at disease onset was present in 17.38% of 
individuals what constitutes over one third of ALS 
patients ever developing EL [11, 46-50].  
For the first time we have shown that EL at the 
disease onset is an independent predictor of faster 
disease progression in ALS. In particular, the presence of 
ELO in patients with bulbar onset resulted mainly in a 
more pronounced progression of bulbar and respiratory 
dysfunction, while in patients with limb onset – the 
bulbar muscles involvement. The risk of developing EL 
at the disease onset was significantly higher for patients 
with bulbar onset ALS. As in numerous studies the 
bulbar onset had been linked to a faster progression of 
ALS, especially at the early disease stage [28, 29], the 
faster disease progression in ELO(+) may result from a 
predominant damage of the brainstem in these patients. 
However, we have observed a significantly faster decay 
of ALSFRS-R in the bulbar onset subgroup with ELO(+) 
as compared to bulbar onset ELO(-) patients. That 
concludes that the EL is a site-of-onset independent 
factor of faster progression in ALS. Moreover, our 
observation supports the hypothesis of a distinct 
mechanism involved in the development of EL and the 
bulbar palsy due to the damage in the brainstem. The 
dysregulation of emotional expression without the 
disturbance of emotional experience is the principal 
feature of EL. Various anatomical structures have been 
reported to be involved in the pathomechanism of EL, 
including the prefrontal cortex, the anterior cingulate, the 
internal capsule, the thalamus, the subthalamic nucleus 
the cerebellum and, most importantly, the paramedial 
part of the brainstem [30]. The pathomechanism is 
complex, as either a lesion or a stimulation of any of 
these structures may result in a sudden impairment of 
emotional expression without concurrent change of the 
individual’s feelings [31-37]. Finally, it is unclear why 
some patients develop solely either laughter or crying 
episodes, while others experience both forms of 
emotional incontinence [11]. 
Although we have not collected data regarding the 
occurrence of depression at the disease onset, we have 
assessed a relationship between the depression and the 
presence of EL at the time of patients’ evaluation. Both 
factors were found to independently affect ALSFRS-R 
decline rate in two-way ANOVA analysis.  
To date, many demographic and disease 
characteristics as predictors of poorer prognosis in ALS 
have been established, including older age, female 
gender, unmarried status, initial weight loss (or 
overweight), diagnostic delay, depression and reduced 
slow vital capacity [26, 38-43]. While some of them are 
commonly reported (e.g. bulbar onset, initial weight 
loss), others remain inconclusive (e.g. female gender, 
depression). In our cohort, we have observed the 
influence of older age, female gender, bulbar onset, 
initial weight loss and shorter diagnostic delay on the 
disease progression. As opposed to other studies [28, 
29], bulbar onset did not reach statistical significance 
(p=0.099) in applied multiple regression model, as the 
older age and shorter diagnostic delay were more 
frequently present in bulbar onset group. 
The main limitation of the current study is the lack 
of linearity of ALSFRS-R decay in the disease course 
and the inhomogeneity of disease progression among 
individual ALS patients [44]. It is not certain if 
prognostic factors affecting ALSFRS-R decline rate 
influence the survival. To date, there has been only one 
study describing a possible impact of EL on the ALS 
outcome [45]. It showed a slightly shorter survival of 
patients with EL, without reaching statistical significance 
(p=0.25). The study did not involve the analysis of the 
disease progression. Its major limitation was a small 
sample size (n=94). Larger group studies are needed to 
explore the relationship between EL and the survival. 
Secondly, although the assessment of the EL was 
preceded by a thorough explanation of this phenomenon 
to individual patients, the question itself may not be fully 
EL-specific, as alike episodes may be observed in 
patients with cognitive impairment or chronic mood 
disturbance. Although there was a high frequency of EL 
among patients with cognitive impairment in our cohort, 
we found comparable results of ECAS among patient 
with and without EL. It is in agreement with the data 
previously reported by Palmieri et al. 2000 [19], who 
showed no correlation between EL and cognitive profile. 
We further found no differences in the ADI-12 scores in 
terms of the occurrence of EL. This all contributes to 
qualifying EL as a distinct condition from the cognitive 
impairment and mood disturbance disorders. 
It remains unclear how the EL contributes to the 
faster progression of the disease. It may depend on 
additional damage to neuronal cells, a greater 
involvement of mechanism particularly affecting 
emotional control areas, or a psychological influence on 
personal attitude towards the disease resulting in a 
poorer outcome [10, 15, 26]. 
In conclusion, the presence of EL at ALS onset 
results in faster disease progression regardless of other 
known demographic and clinical prognostic predictors. 
Thus, the presence of EL requires more insightful care of 
ALS patients, including monitoring of bulbar 
involvement and respiratory function. Moreover, our 
results support the hypothesis of the distinct 
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